Search Results

Dipharma Francis S.r.l. proudly announced that Dipharma Inc., its US facility located in Kalamazoo, MI, has been inspected by the U.S. Food and Drug Administration and has received the Establishment Inspection Report, satisfactorily closing the inspection process.

Dipharma Francis S.r.l., a leading Contract Development and Manufacturing Organization and a global manufacturer of Active Pharmaceutical Ingredients, announced another new production site of the Group, thefacility located in Caronno Pertusella, near Milan, has received the Good Manufacturing Practice certification - CBPF - from the Regulatory Authority of Brazil, ANVISA.

Dipharma Francis S.r.l. announced the completion of the expansion of its Research and Development Center for small molecules at its Headquarters located in Baranzate, close to Milan, in the North of Italy.

Dipharma Francis S.r.l. announced the completion of the second phase of expansion of its American site, Dipharma Inc., located in Kalamazoo, MI.

Dipharma Francis S.r.l. (Dipharma), a leading Contract Development and Manufacturing Organization (CDMO) and a global manufacturer of Active Pharmaceutical Ingredients, announced today that its production site, located in Baranzate, just outside Milan (Italy), has received the Good Manufacturing Practice (GMP) certification, CBPF (Certificado de Boas Práticas de Fabricação), from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária).

Dipharma Francis S.r.l. announced that the Italian Medicines Agency approved the brand-new production line at the cGMP pilot plant suite, located in its facility of Mereto di Tomba.

Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).

Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug Administration.

Broken String Biosciences announced it has entered a research collaboration with the Francis Crick Institute, a world-leading biomedical discovery institute dedicated to understanding the biology underlying health and disease.